X0202 SCHEDULE 13G/A 0001172661-26-002051 0001837309 XXXXXXXX LIVE 2 Common Stock, $0.001 par value per share 03/31/2026 0001672619 ENLIVEN THERAPEUTICS, INC. 29337E102 6200 Lookout Road Boulder CO 80301 Rule 13d-1(c) Polar Capital Holdings Plc X0 5056807.00 0.00 5056807.00 0.00 5056807.00 N 8.46 HC Polar Capital LLP X0 5056807.00 0.00 5056807.00 0.00 5056807.00 N 8.46 IA Polar Capital Funds PLC - Biotechnology Fund X0 5056807.00 0.00 5056807.00 0.00 5056807.00 N 8.46 OO ENLIVEN THERAPEUTICS, INC. 6200 Lookout Road, Boulder, CO 80301 Polar Capital Holdings Plc Polar Capital LLP Polar Capital Funds PLC - Biotechnology Fund 16 Palace Street London, SW1E 5JD George's Court, 54-62 Townsend Street Dublin 2, Ireland United Kingdom Y 5,056,807 8.46% 5,056,807 0 5,056,807 0 Based on 60,904,946 shares outstanding as reported in the Issuer's Form 10-Q on May 7, 2026. Y Y N Information for each Subsidiary is incorporated on the respective cover pages. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Polar Capital Holdings PLC By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital LLP By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital Funds PLC - Biotechnology Fund By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital Holdings Plc /s/ Nicholas Farren 05/15/2026 Polar Capital LLP /s/ Nicholas Farren 05/15/2026 Polar Capital Funds PLC - Biotechnology Fund /s/ Nicholas Farren 05/15/2026